1111637-95-6

Basic information

• Product Name: 3-Methyl-7-azaindole-5-boronic acid
• Synonyms: 3-Methyl-7-azaindole-5-boronic acid;3-Methyl-7-azaindole-5-bo...;3-METHYL-1H-PYRROLO[2,3-B]PYRIDINE-5-BORONIC ACID PINACOL ESTER;3-Methyl-7-azaindole-5-boronic acid pinacol ester;3-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine;3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine
• CAS NO: 1111637-95-6
• Molecular Formula: C8H9BN2O2
• Molecular Weight: 175.98026
• EINECS: 200-589-5
• Mol File: 1111637-95-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 14.18±0.40(Predicted)
• CAS DataBase Reference: 3-Methyl-7-azaindole-5-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-7-azaindole-5-boronic acid(1111637-95-6)
• EPA Substance Registry System: 3-Methyl-7-azaindole-5-boronic acid(1111637-95-6)

Safety Data

• Hazardous Substances Data: 1111637-95-6(Hazardous Substances Data)

Usage

General Description

3-Methyl-7-azaindole-5-boronic acid is a chemical compound with the molecular formula C9H10BNO2. It is a boronic acid derivative of 7-azaindole, which is a heterocyclic compound containing an indole ring with a pyridine ring fused at the 7th position. 3-Methyl-7-azaindole-5-boronic acid is often used as a building block in organic synthesis and pharmaceutical research, as boronic acids are known to be useful for forming carbon-carbon bonds in chemical reactions. Additionally, its 3-methyl substituent can enhance its reactivity and alter its chemical properties, making it a valuable tool for medicinal chemistry and drug discovery efforts. Overall, 3-Methyl-7-azaindole-5-boronic acid is a versatile and important chemical compound with applications in both academic and industrial settings.

Upstream product

• 757978-18-0 3-iodo-5-bromo-1H-pyrrolo[2,3-b]-pyridine 
• 1620574-95-9 5-bromo-3-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-94-8 5-bromo-3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-93-7 (5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol 
• 1207626-51-4 5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1111637-94-5 5-bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.